Business Description
eFFECTOR Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US28202V2079
Description
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.25 | |||||
Equity-to-Asset | 0.03 | |||||
Debt-to-Equity | 24.48 | |||||
Debt-to-EBITDA | -0.64 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Book Growth Rate | 71.3 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 30.93 | |||||
9-Day RSI | 39.11 | |||||
14-Day RSI | 41.76 | |||||
6-1 Month Momentum % | -50.64 | |||||
12-1 Month Momentum % | 0.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.03 | |||||
Quick Ratio | 1.03 | |||||
Cash Ratio | 0.99 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.7 | |||||
Shareholder Yield % | -9140.66 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -148.44 | |||||
ROIC % | -146.54 | |||||
ROC (Joel Greenblatt) % | -10343.79 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.39 | |||||
Price-to-Tangible-Book | 0.39 | |||||
EV-to-EBIT | 0.15 | |||||
EV-to-Forward-EBIT | -0.66 | |||||
EV-to-EBITDA | 0.15 | |||||
EV-to-Forward-EBITDA | -0.66 | |||||
EV-to-FCF | 0.16 | |||||
Earnings Yield (Greenblatt) % | 666.67 | |||||
FCF Yield % | -7449.11 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
eFFECTOR Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -6.968 | ||
Beta | 0 | ||
Volatility % | 132.86 | ||
14-Day RSI | 41.76 | ||
14-Day ATR (€) | 0.777612 | ||
20-Day SMA (€) | 9.9385 | ||
12-1 Month Momentum % | 0.73 | ||
52-Week Range (€) | 7.8 - 33.5 | ||
Shares Outstanding (Mil) | 3 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
eFFECTOR Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
eFFECTOR Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
eFFECTOR Therapeutics Inc Frequently Asked Questions
What is eFFECTOR Therapeutics Inc(STU:LWK)'s stock price today?
The current price of STU:LWK is €9.25. The 52 week high of STU:LWK is €33.50 and 52 week low is €7.80.
When is next earnings date of eFFECTOR Therapeutics Inc(STU:LWK)?
The next earnings date of eFFECTOR Therapeutics Inc(STU:LWK) is 2024-08-08 Est..
Does eFFECTOR Therapeutics Inc(STU:LWK) pay dividends? If so, how much?
eFFECTOR Therapeutics Inc(STU:LWK) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |